NF-κB drives epithelial-mesenchymal mechanisms of lung fibrosis in a translational lung cell model

JCI Insight. 2023 Feb 8;8(3):e154719. doi: 10.1172/jci.insight.154719.

Abstract

In the progression phase of idiopathic pulmonary fibrosis (IPF), the normal alveolar structure of the lung is lost and replaced by remodeled fibrotic tissue and by bronchiolized cystic airspaces. Although these are characteristic features of IPF, knowledge of specific interactions between these pathological processes is limited. Here, the interaction of lung epithelial and lung mesenchymal cells was investigated in a coculture model of human primary airway epithelial cells (EC) and lung fibroblasts (FB). Single-cell RNA sequencing revealed that the starting EC population was heterogenous and enriched for cells with a basal cell signature. Furthermore, fractions of the initial EC and FB populations adopted distinct pro-fibrotic cell differentiation states upon cocultivation, resembling specific cell populations that were previously identified in lungs of patients with IPF. Transcriptomic analysis revealed active NF-κB signaling early in the cocultured EC and FB, and the identified NF-κB expression signatures were found in "HAS1 High FB" and "PLIN2+ FB" populations from IPF patient lungs. Pharmacological blockade of NF-κB signaling attenuated specific phenotypic changes of EC and prevented FB-mediated interleukin-6, interleukin-8, and CXC chemokine ligand 6 cytokine secretion, as well as collagen α-1(I) chain and α-smooth muscle actin accumulation. Thus, we identified NF-κB as a potential mediator, linking epithelial pathobiology with fibrogenesis.

Keywords: Cell Biology; Fibrosis; Pulmonology.

MeSH terms

  • Collagen Type I
  • Fibrosis
  • Humans
  • Idiopathic Pulmonary Fibrosis* / pathology
  • Lung / pathology
  • NF-kappa B* / metabolism
  • Signal Transduction

Substances

  • NF-kappa B
  • Collagen Type I

Grants and funding

All authors, except Dr. Eric S. White are current or former employees of Idorsia Pharmaceuticals Ltd. The authors declare that they have no competing interests